Dishman Carbogen Amcis Limited (DCAL) Share Price
NSE · Healthcare · Biotechnology · ISIN INE385W01011
Key metrics
- Market Cap
- ₹2,740 Cr
- P/E Ratio
- 28.51
- EPS
- 6.13
- Book Value
- 425.87
- P/B Ratio
- 0.42
- ROE
- 1.46%
- ROCE
- 2.33%
- Debt / Equity
- 0.46
- Net Margin
- 3.32%
- Revenue Growth
- 8.13%
- Profit Growth
- 2,907.72%
- Dividend Yield
- —
- 52W High
- ₹321.95
- 52W Low
- ₹128.50
- Market Cap Band
- small cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
- Headquarters
- Ahmedabad, India
- Promoter Holding
- 69.3%
The full Dishman Carbogen Amcis Limited analysis
Create a free account to open the complete DCAL deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.